Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement with Nanjing-based Leads Biolabs and Beijing firm BeiGene Inc., (NASDAQ: BGNE, HKG: 6160). The cooperation focuses on the development and global manufacturing of LBL-007, a LAG-3 monoclonal antibody (mAb).
BeiGene’s Acquisition and Global Rights to LBL-007
BeiGene secured global research, development, and manufacturing rights, along with exclusive commercialization rights outside of China for LBL-007 in a December 2021 deal valued up to USD 772 million. This significant acquisition highlights the potential of LBL-007 in the global oncology market.
Accelerating IND Filings and Clinical Trials
Chime Biologics will provide support to Leads Biolabs to expedite IND filings and clinical trial materials in China. Additionally, BeiGene and Chime Biologics have established a strategic cooperation to facilitate IND applications overseas and supply clinical trial materials. While financial details were not disclosed, this partnership underscores the commitment to advancing LBL-007’s development and global reach.
LBL-007’s Clinical Progress and ASCO Presentation
LBL-007 is currently transitioning from Phase I to Phase II clinical development in China. Data from Phase I trials, which investigated the drug as a treatment for advanced or metastatic melanoma, were presented at this year’s American Society of Clinical Oncology (ASCO) meeting. The presentation at ASCO underscores the clinical significance and progress of LBL-007 in the field of oncology.-Fineline Info & Tech
